7 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow this drug Literature Review of TNP-2092 trials Research Report on TNP-2092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants TNP-2092 for injection, Vancomycin Hydrochloride for Injection, Oral antibiotics - Prosthetic Joint Infection (PJI) | Phase 2 | Not yet recruiting | TenNor Therapeutics (Zhongshan) Limited | 40 | 2026-10-01 | 2026-10-05 |
| A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants TNP-2092 for injection, Vancomycin Hydrochloride for Injection (IA), Vancomycin Hydrochloride for Injection (IV) - Periprosthetic Joint Infection (PJI) | Phase 1 / Phase 2 | Recruiting | TenNor Therapeutics Inc. | 33 | 2025-04-03 | 2026-10-19 |
| Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants TNP-2092 for injection, placebo - Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI) | Phase 1 | Completed | TenNor Therapeutics Inc. | 32 | 2022-07-07 | 2024-05-01 |
| Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty TNP-2092 - Prosthetic Joint Infection | Phase 1 | Completed | TenNor Therapeutics Limited | 13 | 2021-03-01 | 2022-10-19 |
| PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia TNP-2092 capsules, Placebo - Hyperammonemia | Phase 1 / Phase 2 | Completed | TenNor Therapeutics (Suzhou) Limited | 36 | 2020-08-27 | 2025-04-25 |
| TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection TNP-2092, Vancomycin - Skin and Subcutaneous Tissue Bacterial Infections, Gram-Positive Bacterial Infections | Phase 2 | Completed | TenNor Therapeutics Limited | 120 | 2019-04-20 | 2023-12-01 |
| The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets TNP-2092 capsules, TNP-2092 capsules placebo, Rabeprazole sodium enteric-coated tablets - Helicobacter Pylori Infection | Phase 1 | Completed | TenNor Therapeutics Inc. | 20 | 2017-10-10 | 2024-04-01 |
| A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects TNP-2092 capsules, Placebo - Helicobacter Pylori Infection | Phase 1 | Completed | TenNor Therapeutics (Suzhou) Limited | 40 | 2016-11-08 | 2025-02-27 |
| A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules TNP-2092 capsules, TNP-2092 placebo capsules - Hyperammonemia | Phase 1 | Completed | TenNor Therapeutics (Suzhou) Limited | 58 | 2016-06-06 | 2025-04-25 |
Hyperammonemia (2) · Gram-Positive Bacterial Infections (1)
TenNor Therapeutics (Suzhou) Limited (3) · TenNor Therapeutics Inc. (3) · TenNor Therapeutics Limited (2) · TenNor Therapeutics (Zhongshan) Limited (1)
China (7) · United States (2)
Yanhua Ding, MD (3)